Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | PKM | P14618 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578633 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAPKMKDM4ESMN1; SMN2 | |
| SCHEMBL578832 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAPKMKDM4ESMN1; SMN2 | |
| SCHEMBL578728 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAPKMKDM4ESMN1; SMN2 | |
| SCHEMBL579136 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAPKMKDM4ESMN1; SMN2 | |
| SCHEMBL1279062 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAPKMKDM4ESMN1; SMN2 | |
| SCHEMBL633906 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAPKMKDM4ESMN1; SMN2 | |
| SCHEMBL366844 | 0.98 | ALDH1A1 (0.79) | ALDH1A1LMNAPKMKDM4ESMN1; SMN2 | |
| Bicarbonate SCHEMBL9492528 | 0.95 | ALDH1A1 (0.74) | ALDH1A1LMNAPKMKDM4ESMN1; SMN2 | |
| Trimethylammonium SCHEMBL27862582 | 0.95 | ALDH1A1 (0.74) | ALDH1A1LMNAPKMKDM4ESMN1; SMN2 | |
| Bicarbonate SCHEMBL9491178 | 0.95 | ALDH1A1 (0.74) | ALDH1A1LMNAPKMKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996013372-A2 | BUILD MATERIAL FOR FORMING A THREE DIMENSIONAL ARTICLE | BPM TECHNOLOGY, INC. (US) | 1996-05-09 | — | — | WO | claimed |
| US-4820346-A | Ink jet printer ink | HOWTEK, INC. (US) | 1989-04-11 | — | — | US | claimed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8178677-B2 | Hydroxyalkyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178677-B2 | Hydroxyalkyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | COLEY PHARMACEUTICAL GROP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-5969971-A | Apparatus and method for thermal normalization in three-dimensional article manufacturing | BPM TECHNOLOGY, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| WO-1996012607-A1 | APPARATUS AND METHOD FOR THERMAL NORMALIZATION IN THREE-DIMENSIONAL ARTICLE MANUFACTURING | BPM TECHNOLOGY, INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| EP-0656040-A1 | PRINTING INKS AND METHOD OF INK JET PRINTING | THE GENERAL ELECTRIC COMPANY, p.l.c. (GB) | 1995-06-07 | — | — | EP | disclosed |
| EP-0656039-A1 | IONOMER BASED HOT-MELT INKS | THE GENERAL ELECTRIC COMPANY, p.l.c. (GB) | 1995-06-07 | — | — | EP | disclosed |
| US-5385957-A | Adhere to substrates, yield images with good flexibility and smear resistance | VIDEOJET SYSTEMS INTERNATIONAL, INC. (US) | 1995-01-31 | — | — | US | disclosed |
| US-5298062-A | Printing | VIDEOJET SYSTEMS INTERNATIONAL, INC. (US) | 1994-03-29 | — | — | US | disclosed |
| WO-1994004618-A1 | PRINTING INKS AND METHOD OF INK JET PRINTING | THE GENERAL ELECTRIC COMPANY PLC. (GB) | 1994-03-03 | — | — | WO | disclosed |
| WO-1994004619-A1 | IONOMER BASED HOT-MELT INKS | THE GENERAL ELECTRIC COMPANY PLC (GB) | 1994-03-03 | — | — | WO | disclosed |
| US-4820346-A | Ink jet printer ink | HOWTEK, INC. (US) | 1989-04-11 | — | — | US | disclosed |
| US-4713489-A | Preparation of N-substituted arylsulfonamides | AKZO AMERICA INC. (US) | 1987-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | ALDH1A1 1275/4885LMNA 4342/4885PKM 3556/4885 |
| US-20090029988-A1 | Hydroxyalkyl Substituted Imidazoquinolines | IFNG, IRF3, IFNAR1 | ALDH1A1 989/4885LMNA 3293/4885PKM 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.